UBS raised the firm’s price target on United Therapeutics (UTHR) to $580 from $560 and keeps a Buy rating on the shares. The Tyvaso IPF data from the TETON-2 study could drive a positive stock reaction as the best-in-class efficacy and safety was re-confirmed, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Hold Rating Maintained for United Therapeutics’ Tyvaso Amid Competitive Landscape and Pending Data
- CarMax downgraded, Kenvue upgraded: Wall Street’s top analyst calls
- Buy Rating for United Therapeutics Amid Favorable Legal Standing in Patent Litigation
- United Therapeutics initiated with an Outperform at RBC Capital
- United Therapeutics management to meet with Cantor Fitzgerald